Leadartis

Leadartis, founded in 2013 and headquartered in Spain, is making strides in the Biopharma and Biotechnology industries with its cutting-edge technology platform, Trimerbody®. The company specializes in the development of bispecific tumor-targeted antibodies, leveraging its innovative molecular engineering capabilities.

The Trimerbody® platform offers distinct advantages over conventional antibodies by allowing multiple targeting, providing enhanced avidity and stability, and offering diverse effector functionalities. This novel class of therapeutic proteins utilizes antigen-binding domains coupled with collagen trimerization domains for improved therapeutic properties.

Leadartis focuses on areas like immuno-oncology and inflammatory-autoimmune diseases, offering substantial licensing opportunities for biopharmaceutical companies to access its proprietary technology. Despite a robust offering, Leadartis has not disclosed its latest funding round or investors, suggesting a potential opportunity for strategic partners to engage early in its growth phase.